December is coming to an end, looking back on this month, there have been frequent financing events in the medical and health field, such as Dekang Medical completing hundreds of millions of yuan in Series B + financing, Core Medical completing hundreds of millions of yuan in Series C financing, Ladder Medical obtaining hundreds of millions of yuan in Series A financing, Lingfu Bio completing 170 million yuan in A1 round financing, etc.
Dekang Medical completed hundreds of millions of yuan in Series B+ financing
Recently, Dekang Medical, a domestic orthopedic surgery overall solution company, announced the completion of hundreds of millions of yuan in Series B+ financing
.
After this round of financing, Dekang Medical will expand the construction of production and R&D bases, national supply chain and marketing construction, and strengthen product technology and academic advantages
.
This round of financing was led by Fuzhe Capital and its State Reform Fund, followed by Xiuhu Fund, Jiaxin Silk, Yonggui Fund, Lishui Fuzhi Fund, etc
.
EC Capital acted as the exclusive financial advisor
to Dekang Medical in this transaction.
According to the data, Dekang Medical is currently an orthopedic digital platform enterprise
with the original research ability of new materials and new surgical methods in China.
In order to meet the national product supply, the company will soon put into production medical intelligent production R&D base, including Dekang "Yangtze River Delta" orthopedic implant materials and artificial organ manufacturing center, global R&D center, mechanics experiment center and joint testing and inspection center, display and technical training center, etc.
, with a total area of 60,000 square meters, with the production and supply capacity
of millions of orthopedic implant materials every year.
Core Medical completed hundreds of millions of yuan in Series C financing
Recently, Core Medical, a developer of high-end innovative medical device products, announced the completion of hundreds of millions of yuan in Series C financing, which will be mainly used to accelerate the R&D, clinical and commercialization layout of product lines and build an innovative active plant intervention platform
.
This round of financing is jointly invested by private equity institutions and industrial capital such as Henry Zhen Yuan, Cornerstone Capital, Salubris Medical Devices, Nanshan Zhan New Investment, Beihang Capital, etc.
, and existing shareholders Lianxin Capital and Hillhouse Venture Capital continue to invest
more.
According to the data, Core Medical is committed to providing comprehensive solutions
for mechanical circulatory support for heart failure patients.
In terms of artificial heart miniaturization, Core Medical breaks the limitations of the weight and performance of existing products in the field of artificial hearts, solves key technical problems such as hemolysis, thrombosis, anti-infection, and stroke, and goes further in terms of long-term reliability and long-term stability of products, bringing a new generation of ultra-small fully magnetic levitation artificial hearts; At the same time, based on the implanted artificial heart technology platform and the miniaturized motor technology with completely independent intellectual property rights, a new generation of interventional artificial heart series products has been developed; Become a company
that has achieved a comprehensive layout in the field of implantation and interventional artificial heart.
Core Medical has more than 200 independent R&D technology accumulation and five basic R&D technology platforms around the world, starting from actual clinical needs, the company has built a product pipeline covering comprehensive mechanical circulation support for acute and chronic heart failure, covering different support times, different surgical methods, different departments, and different flows; We hope to create high-end medical device products
that are more in line with the needs of patients.
Ladder Medical received hundreds of millions of yuan in Series A financing
Recently, Shanghai Ladder Medical Technology Co.
, Ltd.
(hereinafter referred to as Stairmed), a cutting-edge technology company focusing on the research and development of the underlying technology of a new generation of brain-computer interfaces, recently announced the completion of a series A financing of hundreds of millions of yuan, jointly led by OrbiMed and Yuanhe Origin
.
This round of financing will continue to be used for system research and development and team expansion, and continue to maintain the company's position
in the field of implantable brain-computer interface.
Ladder Medical has obtained tens of millions of yuan in angel round financing
from Yuanlai Capital.
According to the data, Ladder Medical is an implantable brain-computer interface technology developer, committed to developing implantable brain-computer interface systems
that connect the human brain with the outside world.
By establishing a high-bandwidth information channel between the human brain and the outside world, the brain is comprehensively analyzed and understood, so as to realize the two-way interaction
between the brain and peripherals.
Related technologies and products can be applied to human function repair, disease treatment, human function enhancement and other directions
.
Lingfu Biotech completed the A1 round of financing of 170 million yuan
Recently, Beijing Lingfu Biotechnology Co.
, Ltd
.
(hereinafter referred to as "Lingfu Biotechnology") completed a round of financing of RMB 170 million.
The company's financing purposes will be mainly used for the layout of non-human primate resource bases and the construction of experimental facilities, continue to improve the layout of the industrial chain of experimental animal resources, and form a complete closed loop
of NHP resources and service capabilities of psychic creatures.
At the same time, the company completed the strategic integration with Beijing Renyuan Xinsheng, a gene editing animal model company, and made breakthroughs in the development of large-fragment gene editing technology and gene editing animal model development capabilities, forming a more complete technological innovation service capability
.
This round of financing and investment institutions include Hainan Rongzhi Fund, Sanya Yazhou Bay Venture Capital, Heyu Capital, Legend Capital, Puhua Capital, Saifu Pharmaceutical and the founding team
.
Probe Capital acted as financial advisor
to the financing.
According to the data, Lingfu Biotech is committed to building a scientific research service provider
that integrates the whole industry chain of experimental model resources, the whole industry chain of experimental model technology and high value-added innovative scientific research services.
At present, the company's Jiangsu Lingfu Zhaosheng is an experimental dog and marmoset service provider, Chengdu Lingfu Shiye is a characteristic non-human primate supplier, Shenzhen Lingfu Tuopu and Beijing Shouke Lingfu are professional experimental models and animal scientific research service providers, and Beijing Renyuan Xinsheng is an innovative platform based on molecular cell biology technology and gene editing technology, and has initially formed a national experimental model resource base and laboratory and animal room layout
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
